| Type | Title | Date Released | |
|---|---|---|---|
6-K | Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC® in Israel New | ||
6-K | Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC® at 8th ICRS Summit in Portugal | ||
EFFECT | Form EFFECT | ||
POS AM | SHARE RESALE REGISTRATION | Shares: 3,807,143 EFFECTIVE, DATED 2026-09-22 | ||
6-K | Regentis Biomaterials Reports First Half 2026 Financial Results and Corporate Update | ||
SCHEDULE 13G | Rosalind Advisors, Inc. (Filed by) | ||
S-8 | Form S-8 | ||
6-K | Regentis Receives Japanese Patent Allowance for Proprietary GelrinC Manufacturing Technology | ||
6-K | Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process | ||
EFFECT | Form EFFECT | ||
4 | Alpert Susan PHD MD (Reporting) | ||
424B3 | SHARE RESALE REGISTRATION | Shares: 3,807,143 | Bank: ThinkEquity LLC |
